On April 27, 2023 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that it will report financial results for the first quarter ended March 31, 2023, on Thursday, May 4, 2023 after the close of the US market (Press release, Cellectis, APR 27, 2023, View Source [SID1234630596]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The announcement will be followed by an investor conference call and webcast on Friday, May 5, 2023 at 8:00 am ET / 2:00 pm CET. The call will include the Company’s first quarter results and an update on business activities. Details for the call are as follows:

Dial-in Information:

Domestic:

1-877-451-6152

International:

1-201-389-0879

Conference ID:

13737755

Webcast Link:

View Source;tp_key=92e9a57eb8